Zip, thinking about how are sales in the EU are stuck in the mud (non existent really), and your statement about keeping the price of V low worldwide, I am wondering what the net ramifications would have been if Amarin just went ahead and accepted the significantly lower reimbursement from Germany? We could have been selling V there now, but it may have affected some other countries and their reimbursements. But at the same time may have spurred Spain, Italy, France to be more receptive to V reimbursement at a lower rate. Of course, as you say, this would be more feasible for a big pharma than Amarin.
Reading the sobering post from Tatsumaki (sp?) which I think accurately describes the current state of affairs, I keep thinking about Denner and his stock purchases going back a year and a half. Of course things are worse now in Europe but I am hoping that Denner saw all these hurdles when he bought in and hopefully has a plan to get us out of this pickle. Some believe that Amarin has to get the EU rolling first (reimbursements) before a large pharma in the EU would be interested to take over, but it seems to me that a big EU pharma could handle this rollout in a much superior fashion. Of course if they have to do all the work the should not have to pay as much to buy Amarin.
Market Data 
Markets 
